Literature DB >> 33544209

Honokiol antagonizes doxorubicin resistance in human breast cancer via miR-188-5p/FBXW7/c-Myc pathway.

Xianglan Yi1, Liping Lou1, Jun Wang1, Jing Xiong2, Sheng Zhou3.   

Abstract

BACKGROUND: Honokiol, a natural phenolic compound derived from Magnolia plants, is a promising anti-tumor compound that exerts a wide range of anti-cancer effects. Herein, we investigated the effect of honokiol on doxorubicin resistance in breast cancer.
METHODS: Doxorubicin-sensitive (MCF-7 and MDA-MB-231) and doxorubicin-resistant (MCF-7/ADR and MDA-MB-231/ADR) breast cancer cell lines were treated with doxorubicin in the absence or presence of honokiol; then, the following tests were performed: flow cytometry for cell apoptosis, WST-1 assay for cell viability, qPCR and western blot for the expression of miR-188-5p, FBXW7, and c-Myc. MiR-188-5p mimic, miR-188-5p inhibitor, siFBXW7, and c-Myc plasmids were transfected into cancer cells to evaluate whether miR-188-5p and FBXW7/c-Myc signaling are involved in the effect of honokiol on doxorubicin resistance in breast cancer. A dual luciferase reporter system was used to study the direct interaction between miR-188-5p and FBXW7.
RESULTS: Honokiol sensitized doxorubicin-resistant breast cancer cells to doxorubicin-induced apoptosis. Mechanically, upregulation of miR-188-5p was associated with doxorubicin resistance, and honokiol enhanced doxorubicin sensitivity by downregulating miR-188-5p. FBXW7 was confirmed to be a direct target gene of miR-188-5p. FBXW7/c-Myc signaling was involved in the chemosensitization effect of honokiol. Honokiol induced apoptosis in MCF-7/ADR and MDA-MB-231/ADR cells. However, FBXW7 silencing or c-Myc transfection resulted in resistance to the honokiol-induced apoptotic effect.
CONCLUSION: These findings suggest that downregulation of miR-188-5p by honokiol enhances doxorubicin sensitivity through FBXW7/c-Myc signaling in human breast cancer. Our study finds an important role of miR-188-5p in the development of doxorubicin resistance in breast cancer, and enriches our understanding of the mechanism of action of honokiol in cancer therapy.

Entities:  

Keywords:  Breast cancer; C-myc; Chemoresistance; FBXW7; Honokiol; MiR-188-5p

Mesh:

Substances:

Year:  2021        PMID: 33544209     DOI: 10.1007/s00280-021-04238-w

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  34 in total

1.  The Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated degradation and suppresses breast cell proliferation.

Authors:  Dong Zhao; Han-Qiu Zheng; Zhongmei Zhou; Ceshi Chen
Journal:  Cancer Res       Date:  2010-05-18       Impact factor: 12.701

2.  Chemotherapy induces enrichment of CD47+/CD73+/PDL1+ immune evasive triple-negative breast cancer cells.

Authors:  Debangshu Samanta; Youngrok Park; Xuhao Ni; Huili Li; Cynthia A Zahnow; Edward Gabrielson; Fan Pan; Gregg L Semenza
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-24       Impact factor: 11.205

Review 3.  FBXW7 in Cancer: What Has Been Unraveled Thus Far?

Authors:  Bethsebie Lalduhsaki Sailo; Kishore Banik; Sosmitha Girisa; Devivasha Bordoloi; Lu Fan; Clarissa Esmeralda Halim; Hong Wang; Alan Prem Kumar; Dali Zheng; Xinliang Mao; Gautam Sethi; Ajaikumar Bahulayan Kunnumakkara
Journal:  Cancers (Basel)       Date:  2019-02-19       Impact factor: 6.639

Review 4.  Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.

Authors:  Giampaolo Bianchini; Justin M Balko; Ingrid A Mayer; Melinda E Sanders; Luca Gianni
Journal:  Nat Rev Clin Oncol       Date:  2016-05-17       Impact factor: 66.675

Review 5.  FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation.

Authors:  Markus Welcker; Bruce E Clurman
Journal:  Nat Rev Cancer       Date:  2008-02       Impact factor: 60.716

6.  Gliomagenesis arising from Pten- and Ink4a/Arf-deficient neural progenitor cells is mediated by the p53-Fbxw7/Cdc4 pathway, which controls c-Myc.

Authors:  Hong Sug Kim; Kevin Woolard; Chen Lai; Peter O Bauer; Dragan Maric; Hua Song; Aiguo Li; Svetlana Kotliarova; Wei Zhang; Howard A Fine
Journal:  Cancer Res       Date:  2012-09-17       Impact factor: 12.701

7.  The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability.

Authors:  Bryan King; Thomas Trimarchi; Linsey Reavie; Luyao Xu; Jasper Mullenders; Panagiotis Ntziachristos; Beatriz Aranda-Orgilles; Arianne Perez-Garcia; Junwei Shi; Christopher Vakoc; Peter Sandy; Steven S Shen; Adolfo Ferrando; Iannis Aifantis
Journal:  Cell       Date:  2013-06-20       Impact factor: 41.582

8.  MYC Is a Major Determinant of Mitotic Cell Fate.

Authors:  Caroline Topham; Anthony Tighe; Peter Ly; Ailsa Bennett; Olivia Sloss; Louisa Nelson; Rachel A Ridgway; David Huels; Samantha Littler; Claudia Schandl; Ying Sun; Beatrice Bechi; David J Procter; Owen J Sansom; Don W Cleveland; Stephen S Taylor
Journal:  Cancer Cell       Date:  2015-07-13       Impact factor: 31.743

9.  MYC is a critical target of FBXW7.

Authors:  Mai Sato; Ruth Rodriguez-Barrueco; Jiyang Yu; Catherine Do; Jose M Silva; Jean Gautier
Journal:  Oncotarget       Date:  2015-02-20

10.  Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers.

Authors:  Bradley A Hancock; Yu-Hsiang Chen; Jeffrey P Solzak; Mufti N Ahmad; David C Wedge; Dumitru Brinza; Charles Scafe; James Veitch; Rajesh Gottimukkala; Walt Short; Rutuja V Atale; Mircea Ivan; Sunil S Badve; Bryan P Schneider; Xiongbin Lu; Kathy D Miller; Milan Radovich
Journal:  Breast Cancer Res       Date:  2019-08-05       Impact factor: 6.466

View more
  7 in total

Review 1.  Recent Insight on Regulations of FBXW7 and Its Role in Immunotherapy.

Authors:  Liangliang Xing; Leidi Xu; Yong Zhang; Yinggang Che; Min Wang; Yongxiang Shao; Dan Qiu; Honglian Yu; Feng Zhao; Jian Zhang
Journal:  Front Oncol       Date:  2022-06-24       Impact factor: 5.738

2.  The Role of miRNAs in the Resistance of Anthracyclines in Breast Cancer: A Systematic Review.

Authors:  Zihan Si; Yan Zhong; Sixian Lao; Yufeng Wu; Guoping Zhong; Weiwei Zeng
Journal:  Front Oncol       Date:  2022-05-12       Impact factor: 5.738

3.  Salidroside overcomes dexamethasone resistance in T-acute lymphoblastic leukemia cells.

Authors:  Ya-Na Niu; Yan Zeng; Fang-Fang Zhong; Si-Li Long; Dan-Wei Ren; Xiang Qin; Wen-Jun Liu
Journal:  Exp Ther Med       Date:  2021-04-15       Impact factor: 2.447

Review 4.  Immune Effect of Active Components of Traditional Chinese Medicine on Triple-Negative Breast Cancer.

Authors:  Wenjie Zhao; Jinhua Liu; Yaqun Li; Zichao Chen; Dongmei Qi; Zhen Zhang
Journal:  Front Pharmacol       Date:  2021-12-03       Impact factor: 5.810

5.  Honokiol Inhibits HIF-1α-Mediated Glycolysis to Halt Breast Cancer Growth.

Authors:  Xianglan Yi; Mengxin Qi; Mingxiang Huang; Sheng Zhou; Jing Xiong
Journal:  Front Pharmacol       Date:  2022-03-08       Impact factor: 5.810

6.  Paeoniflorin Enhances the Sensitivity of ER-Positive Breast Cancer Cells to Tamoxifen through Promoting Sirtuin 4.

Authors:  Pei Zhang; Nan Wu; Zhi-Jun Song; Zheng-Fu Tai
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-15       Impact factor: 2.629

Review 7.  FBXW7 and the Hallmarks of Cancer: Underlying Mechanisms and Prospective Strategies.

Authors:  Wenyue Shen; Quanwei Zhou; Chenxi Peng; Jiaheng Li; Qizhi Yuan; Hecheng Zhu; Ming Zhao; Xingjun Jiang; Weidong Liu; Caiping Ren
Journal:  Front Oncol       Date:  2022-04-19       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.